Entellus Medical Inc (ENTL) Stake Increased by BlackRock Inc.

BlackRock Inc. grew its holdings in Entellus Medical Inc (NASDAQ:ENTL) by 10.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 676,740 shares of the medical technology company’s stock after buying an additional 64,681 shares during the period. BlackRock Inc. owned 2.63% of Entellus Medical worth $16,506,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Gabelli Funds LLC bought a new position in shares of Entellus Medical during the fourth quarter worth approximately $8,473,000. State Street Corp increased its stake in shares of Entellus Medical by 26.4% during the second quarter. State Street Corp now owns 140,856 shares of the medical technology company’s stock worth $2,333,000 after purchasing an additional 29,386 shares during the period. Havens Advisors LLC bought a new position in shares of Entellus Medical during the fourth quarter worth approximately $1,684,000. Neuberger Berman Group LLC increased its stake in shares of Entellus Medical by 152.2% during the third quarter. Neuberger Berman Group LLC now owns 58,000 shares of the medical technology company’s stock worth $1,071,000 after purchasing an additional 35,000 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its stake in shares of Entellus Medical by 13.6% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 45,129 shares of the medical technology company’s stock worth $1,101,000 after purchasing an additional 5,416 shares during the period. 83.44% of the stock is owned by institutional investors.

How to Become a New Pot Stock Millionaire

Entellus Medical stock opened at $24.00 on Friday. Entellus Medical Inc has a one year low of $11.47 and a one year high of $25.58. The company has a quick ratio of 1.71, a current ratio of 1.92 and a debt-to-equity ratio of 0.32.

A number of equities analysts have recently weighed in on ENTL shares. Zacks Investment Research upgraded Entellus Medical from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th. BidaskClub upgraded Entellus Medical from a “strong sell” rating to a “sell” rating in a research note on Monday, February 5th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $20.33.

TRADEMARK VIOLATION NOTICE: “Entellus Medical Inc (ENTL) Stake Increased by BlackRock Inc.” was published by Week Herald and is the property of of Week Herald. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://weekherald.com/2018/04/20/entellus-medical-inc-entl-stake-increased-by-blackrock-inc.html.

Entellus Medical Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Want to see what other hedge funds are holding ENTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Entellus Medical Inc (NASDAQ:ENTL).

Institutional Ownership by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply